Evidence map›Paper›PMID 33815363›Full record

Trial reportFrontiers in immunology2021

Cytokine Profiles and Antibody Response Associated to Choclo Orthohantavirus Infection.

Tybbysay P Salinas, Jose L Garrido, Jacqueline R Salazar, Publio Gonzalez, Nicole Zambrano, Francisco Fuentes-Villalobos, Felipe Bravo, Victor Fica-Leon, Alexis Salas-Burgos, Mario Calvo and 3 more

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Pseudotyped Viruses for Orthohantavirus.Advances in experimental medicine and biology · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Tybbysay P SalinasDepartment of Microbiology, Biotechnology Center, Faculty of Biological Science, Universidad de Concepción, Concepción, Chile.
Jose L GarridoDepartment of Microbiology, Biotechnology Center, Faculty of Biological Science, Universidad de Concepción, Concepción, Chile.
Jacqueline R SalazarDepartment of Research in Emerging and Zoonotic Diseases, Gorgas Memorial Institute of Health Studies, Panama City, Panama.
Publio GonzalezDepartment of Research in Emerging and Zoonotic Diseases, Gorgas Memorial Institute of Health Studies, Panama City, Panama.
Nicole ZambranoDepartment of Microbiology, Biotechnology Center, Faculty of Biological Science, Universidad de Concepción, Concepción, Chile.
Francisco Fuentes-VillalobosDepartment of Microbiology, Biotechnology Center, Faculty of Biological Science, Universidad de Concepción, Concepción, Chile.
Felipe BravoDepartment of Microbiology, Biotechnology Center, Faculty of Biological Science, Universidad de Concepción, Concepción, Chile.
Victor Fica-LeonDepartment of Pharmacology, Faculty of Biological Sciences, Universidad de Concepción, Concepción, Chile.
Alexis Salas-BurgosDepartment of Pharmacology, Faculty of Biological Sciences, Universidad de Concepción, Concepción, Chile.
Mario CalvoInstitute of Medicine, Universidad Austral de Chile, Valdivia, Chile.
Raymond AlvarezIchor Biologics LLC, New York, NY, United States.
Blas ArmienDepartment of Research in Emerging and Zoonotic Diseases, Gorgas Memorial Institute of Health Studies, Panama City, Panama.
Maria Ines BarriaDepartment of Microbiology, Biotechnology Center, Faculty of Biological Science, Universidad de Concepción, Concepción, Chile.
University of Concepción · CLInstituto Conmemorativo Gorgas de Estudios de la Salud · PAAustral University of Chile · CLSecretaría Nacional de Ciencia, Tecnología e Innovación · PA

Funding

Development of broadly neutralizing antibodies to treat hantavirus infectionsR43AI138740 · NIAID · ICHOR BIOLOGICS, LLC · PI ALVAREZ, RAYMOND · 2019 to 2020
$355k
NIAID NIH HHS R43 AI138740
6 · The paper itself

Abstract

Background: New World Hantaviruses (NWHs) are the etiological agent underlying hantavirus cardiopulmonary syndrome (HCPS), a severe respiratory disease with high mortality rates in humans. In Panama, infections with Methods: For this retrospective study, sera from fifteen individuals with acute CHOV-induced HCPS, were analyzed alongside sera from fifteen convalescent phase individuals and thirty-three asymptomatic, CHOV-seropositive individuals. Cytokine profiles were analyzed by multiplex immunoassay. Antibody subclasses, binding, and neutralization against CHOV-glycoprotein (CHOV-GP) were evaluated by ELISA, and flow cytometry. Results: High titers of IFNγ, IL-4, IL-8, and IL-10 serum cytokines were found in the acute individuals. Elevated IL-4 serum levels were found in convalescent and asymptomatic seropositive individuals. High titers of IgG1 subclass were observed across the three cohorts analyzed. Neutralizing antibody response against CHOV-GP was detectable in few acute individuals but was strong in both convalescent and asymptomatic seropositive individuals. Conclusion: A Th1/Th2 cytokine signature is characteristic during acute mild HCPS caused by CHOV infection. High expression of Th2 and IL-8 cytokines are correlated with clinical parameters in acute mild HCPS. In addition, a strong IL-4 signature is associated with different cohorts, including asymptomatic individuals. Furthermore, asymptomatic individuals presented high titers of neutralizing antibodies.

Indexed as

Antibodies, ViralCytokinesHantavirus InfectionsImmunoglobulin GOrthohantavirusAdultFemaleHumansMaleMiddle AgedTh1 CellsTh2 CellsAntibodies, ViralCytokinesImmunoglobulin GCHOVHCPSIgGIL-10IL-4IL-8neutralizing antibodies

Identifiers

PMID33815363
PMCPMC8017165
OpenAlexW3136080586

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.